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Abstract
Hepatic hemangioma, adenoma and focal nodular hyperplasia are the most frequent benign lesions of the liver, but 
they are all infrequent among pediatric population. The reports of focal nodular hyperplasia in children have recently 
increased in number, with many cases associated to drug intake, particularly to chemotherapy. We here describe, to 
our knowledge, the first case of focal nodular hyperplasia in association with diabetes mellitus in childhood.
Background
The focal nodular hyperplasia (FNH) first described by
Edmondson in 1956, accounts for 8% of primary hepatic
tumors in adults and less than 2% in children. Nonethe-
less, its evidence in pediatric population is increasing
with more than eighty cases described in the last 5 years.
The pathogenesis of FNH is largely unknown. Evidences
of polyclonality in different DNA studies exclude a neo-
plastic nature of the lesion and further support the
hypothesis of a possible reactive hyperplastic response of
liver cells to local vessel abnormality. Chemotherapy and/
or radiotherapy may be associated with development of
FNH and, as clarified by a case-control study, also smoke
may play a pathogenetic role [1]. The association with
estroprogestinic therapies is still debated [2].
Case presentation
A.L., male, suffering from type 1 diabetes mellitus since
he was 7 years old; the disease was metabolically com-
pensated with stable insulin doses. At the age of 12 he
was admitted for abdominal pain and a voluminous mass
in right hypochondria was found; he was in good general
conditions (32 kg of weight) and remaining physical
examination was normal. His insulin requests were: regu-
lar insulin 5 IU before breakfast, 10 IU before lunch and 6
IU before dinner; NPH insulin 16 IU at bedtime. The liver
ultrasound scan showed, at the VI liver segment, two
hypo-isoechogenous oval lesions whose diameters were,
respectively, 83 × 43 mm and 77 × 38 mm. CT scan (Fig.
1A, B) confirmed the presence of two masses, with an
evidence of tumor capsule, that, after contrast injection,
were hyperdense in early (arterial) phase and isodense,
compared to the remaining liver parenchyma, in venous
phase; it also highlighted a central hypodense "scar".
Routine blood tests were all normal and the detection
of serological markers of HAV, HBV, HCV, HIV and
CMV was negative: CEA and αFP were also negative. On
the basis of the mild abdominal pain, and also for a formal
request of parents, the child underwent surgical interven-
tion: the two masses were completely removed. The gross
a p p e a r a n c e  w a s  t h a t  o f  l o b u l a t e d ,  w e l l  c i r c u m s c r i b e d
masses, lacking a fibrous pseudocapsule and showing a
central scar with fibrous septa running to the periphery
and partially demarcating nodular structures. At histo-
logic analysis, both lesions were classic FNH showing a
nodular hyperplastic parenchyma with a typical central
fibrous scar, containing a proliferation of small bile ducts,
irregular tortuous arteries with thickened walls, veins and
capillaries. A discrete inflammatory infiltrate filled the
fibrous septa surrounding the hepatocytic nodules (Fig.
2A, B). The child had a fully satisfactory post-surgery
course in terms of metabolic compensation. The out-
break of fever justified a treatment with broad-spectrum
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antibiotic. After 7 years the child is in good health and no
recurrence has been noted.
Discussion
F N H  i s  v e r y  r a r e  i n  p e d i a t r i c  p o p u l a t i o n  w i t h  a n  a g e
prevalence in children 7-8 years old, although some cases
are diagnosed in early childhood or even in the prenatal
period [3]. The female sex is predominant with a M/F
ratio of less than 1/10 in one of the largest series [4]. The
cause is unknown although the hypothesis that obstruc-
tion of hepatic vessels or abnormal vascularization could
account for FNH is suggested by the reported association
with clinical and anatomic findings like hypoplasia or
agenesis of the portal vein, vascular malformations,
hemangioma and vascular dysplasia, Budd-Chiari syn-
drome and hereditary hemorrhagic telangiectasia [5,6].
Moreover, recent studies reported angiopoietin-1 (Ang-
1) gene and angiopoietin-2 (Ang-2) involvement in the
regulation of vasculogenesis in FNH, with Ang-1/Ang-2
ratio increase in FNH compared with normal liver and
benign or malignant hepatocellular neoplasms [7]. Lastly,
not only it is proved that FNH is more frequent in females
and after oral contraceptive but also there are evidences
that estrogens may induce hepatic angiogenesis in the rat
[8]. All in all, it is possible to assume that pathogenetic
mechanisms may be related to an hyperplastic response
to hemodynamic disturbances due to local factors (eg,
vascular abnormalities or local venous thrombosis with
subsequent arteriovenous shunts) or systemic factors (eg,
oral contraceptives and angiogenic molecules) [5]. As it is
known that diabetes typically is a risk factor for arterial
stiffening and vein thrombosis it is possible to speculate
that the association of diabetes and FNH could be not
completely incidental [9]. It is a bit intriguing to note that
HNF1α, a tumour suppressor gene, whose abnormal
expression could enhance tumorigenesis, is inactivated in
35-50% of all liver adenomas, which are, like FNH, much
more frequent in women taking oral contraceptives:
moreover germline mutation of HNF1α can be associated
with maturity onset diabetes of the young 3 (MODY3).
Taking together this data can resume a final model where
anomalies in gluconeogenesis, glycolysis and lipogenesis
(all typical of diabetes), female sex and oral contracep-
tives may contribute to hemodynamic anomalies and to
the subsequent development of benign neoplasms like
FNH and adenoma.
The majority (70-90%) of FNH at presentation is
asymptomatic and the most common way that the dis-
ease is discovered is when, during an occasional physical
examination, hepatomegaly or a palpatory abdominal
mass are detected. More rarely the disease is diagnosed
after the occurrence of abdominal pain, even though this
event appears not exceptional in pediatric age. Almost
ever the liver function tests are normal. The lesion is
more often unique, but about 8% of cases may show mul-
tiple nodules, up to 30. The diameter of lesions is
extremely variable, from less than 1 cm to more than 15
cm but usually is less than 5 cm.
Some cases of associations with specific disorders or
therapies, have been published:
1. Glycogen storage disease type I: described up to
now about 10 cases.
2. Infrequent cases reported in association to adrenal
cancer, adrenal pseudocyst or Cushing's syndrome.
3. Rare and doubtful cases in association with
drepanocytosis.
4. Three cases reported after portoenterostomy for
biliary atresia.
5. Some cases reported after intake of drugs such as
clomifene, busulfan and especially androgens.
6. A plenty of pediatric cases detected after chemo-
therapy as well as after Hematopoietic Stem Cell
Transplantation (HSCT) [10].
7. Only five cases of association with diabetes mellitus
have been reported until now: three cases were men-
tioned into a series of 28 Swedish patients, another
one was a German 62-year old woman with long-
term diabetes and the fifth was an Australian patient
Figure 1 Abdomen CT scan showed two masses, with an evi-
dence of tumor capsule, that, after contrast injection, were hy-
perdense in early (arterial) phase (A) and isodense, compared to 
the remaining liver parenchyma, in venous phase (B); it also high-
lighted a central hypodense "scar".
AB
Figure 2 Both lesions (A, B) were classic FNH showing a nodular 
hyperplastic parenchyma with a typical central fibrous scar, con-
taining a proliferation of small bile ducts, irregular tortuous arter-
ies with thickened walls, veins and capillaries. A discrete 
inflammatory infiltrate filled the fibrous septa surrounding the hepato-
cytic nodules.
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[11-13]. They were all adult with typical type 2 diabe-
tes.
Different histological variants of FNH are recognized:
the classic, the most frequent and corresponding to the
present case, the not classic, including FNH with cyto-
logic atypia, and mixed hyperplastic and adenomatous
FNH. The so-called telangiectatic FNH is now considered
a variant of adenoma [14].
Classic FNH is characterized by hepatocellular trabecu-
lae forming nodules separated by fibrous septae radiating
from a central fibrous scar. The lesion is generally well
circumscribed, without a capsule but surrounded by a
rim of compressed parenchyma. The central scar may be
absent or inconspicuous in many cases. The evidence of a
typical vascular component is an important feature, prob-
ably related to the vascular malformative pathogenesis of
the lesion.
With modern equipment, the diagnosis is easy in the
majority of cases:
1. Ultrasound. Typical FNH is a mass with variable
echogenicity and the typical hyperechogenic central
scar. Moreover, with the doppler, the presence of
areas of hypervascularization is appreciated in about
50% of the cases. The flow is predominantly arterio-
sus type, with high-speed and low resistance and irra-
diation from the center to the periphery. With the
contrast enhanced ultrasound the typical pattern is
characterized by an high arterial and portal venous
enhancement.
2. CT scan. Hyperintense lesion after administration
of contrast; there is often an immediate contrast
enhancement, mostly isodense, with high initial
attenuation. There is also the ability to detect, when it
is present, the hypodense area of the central scar. So it
is possible to say that typical FNH lesions have homo-
geneous enhancement in hepatic arterial phase, pres-
ence of central scar, and delayed enhancement, while
t h e  a t yp i c a l  F N H ,  m o r e  f r eq u e n t  i n  m a l e  s e x,  m a y
show heterogeneous immediate enhancement,
absence of central scar, or presence of pseudocapsule
[4].
3. MRI. The enhancement after injection of contrast
tends to be early, intense and homogeneous and the
l e s i o n  a p p e a r s  m o r e  f r e q u e n t l y  a s  i s o i n t e n s e  o r
hypointense in T1 and isointense or slightly hyperin-
tense in T2, even if atypical presentations are possi-
ble.
Needle-biopsy or open air biopsy are necessary when
the radiological investigations are doubtful, above all in
case of absence of the central scar, and not rarely the dif-
ferential diagnosis from other nodular lesions of liver may
be difficult. The differential diagnosis includes different
nodular lesions of the liver.
Nodular regenerative hyperplasia (NRH) is a disease
characterized by multiple nodules composed by hepato-
cytes, without a fibrous tissue or central scar [15]. It is
often associated to patients suffering of inflammatory
bowel disease treated with thioguanine or azathioprine or
systemic diseases, above all connective tissue diseases,
such as LES, Polyarteritis nodosa, Antiphospholipid Syn-
drome, Rheumatoid Arthritis or Felty's Syndrome. The
rare pediatric cases are mostly in association with the
congenital absence of portal vein (sometimes compli-
cated by heart disease or multicystic kidney dysplasia).
CT presentation is really different from FNH, as there are
multiple hypodense lesions with poor or absent enhance-
ment after contrast administration [15].
The typical imaging showing anechogenic and regular
profile of the mass at ultrasound, easily recognize cystic
lesions: however CT and MRI may be necessary in
selected cases.
In haemangiomas a doppler ultrasound test is diagnos-
tic almost ever. At CT scan the contrast enhancement
proceeds typically from center to periphery. Nonetheless
in adults and, exceptionally, in children, it is possible to
have a concomitance of FNH and haemangioma.
Radiological findings play a key role also in the diagno-
sis of Adenoma (HCA). At ultrasound there is not the
central scar and the doppler effect is predominantly
venous type with either continuous or pulsatile periph-
eral flow: typically absent is the portal venous enhance-
ment at the contrast enhanced ultrasound. MRI and CT
may also highlight spots of hemorrhage and necrosis. The
differential diagnosis is crucial, because the adenoma is at
risk of breaking, haemorrhage, and malignant transfor-
mation. Surprisingly there are uncommon cases of simul-
taneous detection of adenoma and FNH. Moreover, the
ductular proliferation may be minimal in some FNH at
histological examination, making the differential diagno-
sis difficult [14].
Hepatoblastoma, the most frequent liver tumor in
childhood, is almost always associated to α-fetoprotein
(α-FP) increase and there is not the central scar at CT
scan. Similarly to what happen in adenoma, there are
exceptional cases of concomitant presence of hepatoblas-
toma and FNH. The hepatocellular carcinoma, excep-
tional in pediatric population and often associated with
α-FP increase, at the CT scan shows an hypodense lesion
with a less prompt contrast enhancement than FNH and,
at MRI, an heterogeneous initial enhancement after con-
trast injection.
The natural evolution of FNH is unpredictable even if
the mass, in about 2/3 of cases, remains stable and in
about 1/3-1/4 of cases shows a gradual spontaneous
improvement as far as a complete remission; it is rare an
increase in number as well as in size [9].Farruggia et al. Italian Journal of Pediatrics 2010, 36:41
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The recent studies in molecular biology have confirmed
that FNH is not a pre-neoplastic lesion: the tissue
parenchimal organization is pretty the same of usual liver
tissue and, moreover, even though in some cases a clonal
origin of FNH nodules have been demonstrated, until
now no somatic mutation in the β-catenin gene or in the
other genes implicated in the hepatocellular adenoma
(where a malignant transformation is possible) have been
discovered [5,16]. Moreover the gene expression profile
in FNH shows an activation in β-catenin pathway limited
to the enlarged perivenous areas and completely different
with respect to the other hepatocellular benign lesions
[17].
About the management the first step is, of course, the
stop of oral contraceptive. Considering the body of evi-
dence that FNH doesn't undergo malignant transforma-
tion and that there are only sporadic cases followed by
spontaneous rupture and consequent abdominal bleed-
ing, we agree with the opinion that in asymptomatic cases
it is opportune a careful follow-up with an ultrasound
scan every 6-12 months, and that elective surgery has
probably to be limited to the patients suffering of abdom-
inal pain or with a voluminous or growing mass [5]. It is
worth to note that recurrences are very rare after surgical
removal. When surgical resection is impossible due to
patient factors or location and size of the tumor, selective
arterial embolization should be considered. Finally it is
possible that novel drugs or other radiological therapies
like radio frequency ablation will be available in the
future.
We think that reporting children with FNH may be
helpful to provide to clinicians data useful for the differ-
ential diagnosis process and for the therapeutic decisions:
remarkably this is the sixth case of FNH associated to dia-
betes, the first, at our knowledge, in a child.
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